PCI Biotech Holding ASA (PCIB.OL)
NOK 1.42
(-1.39%)
NOK 1.42
(-1.39%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -20.31 Million NOK | 62.2% |
| 2022 | -53.74 Million NOK | 39.26% |
| 2021 | -88.48 Million NOK | -21.81% |
| 2020 | -72.63 Million NOK | 18.62% |
| 2019 | -89.25 Million NOK | -156.62% |
| 2018 | -34.78 Million NOK | 18.82% |
| 2017 | -42.84 Million NOK | -33.11% |
| 2016 | -32.18 Million NOK | -0.82% |
| 2015 | -31.92 Million NOK | 10.93% |
| 2014 | -35.84 Million NOK | -29.82% |
| 2013 | -27.6 Million NOK | -9.3% |
| 2012 | -25.25 Million NOK | -83.72% |
| 2011 | -13.74 Million NOK | 1.37% |
| 2010 | -13.94 Million NOK | 7.16% |
| 2009 | -15.01 Million NOK | -32.0% |
| 2008 | -11.37 Million NOK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -3.7 Million NOK | 13.02% |
| 2024 Q2 | -3.7 Million NOK | 0.0% |
| 2023 Q2 | -5.75 Million NOK | -4.08% |
| 2023 FY | -20.31 Million NOK | 62.2% |
| 2023 Q4 | -4.25 Million NOK | 0.0% |
| 2023 Q3 | -4.25 Million NOK | 26.12% |
| 2023 Q1 | -5.53 Million NOK | 12.65% |
| 2022 Q4 | -6.33 Million NOK | 39.36% |
| 2022 FY | -53.74 Million NOK | 39.26% |
| 2022 Q1 | -23.22 Million NOK | 7.29% |
| 2022 Q2 | -13.74 Million NOK | 40.83% |
| 2022 Q3 | -10.44 Million NOK | 23.99% |
| 2021 Q4 | -25.04 Million NOK | -16.92% |
| 2021 Q2 | -18.14 Million NOK | 23.67% |
| 2021 Q1 | -23.77 Million NOK | 10.17% |
| 2021 FY | -88.48 Million NOK | -21.81% |
| 2021 Q3 | -21.42 Million NOK | -18.06% |
| 2020 Q2 | -28.99 Million NOK | -755.0% |
| 2020 Q3 | -21.2 Million NOK | 26.88% |
| 2020 Q4 | -26.46 Million NOK | -24.81% |
| 2020 FY | -72.63 Million NOK | 18.62% |
| 2020 Q1 | 4.42 Million NOK | 117.42% |
| 2019 FY | -89.25 Million NOK | -156.62% |
| 2019 Q2 | -26.24 Million NOK | -14.99% |
| 2019 Q4 | -25.4 Million NOK | -78.03% |
| 2019 Q3 | -14.27 Million NOK | 45.62% |
| 2019 Q1 | -22.82 Million NOK | -376.1% |
| 2018 FY | -34.78 Million NOK | 18.82% |
| 2018 Q4 | -4.79 Million NOK | 42.49% |
| 2018 Q3 | -8.33 Million NOK | -17.24% |
| 2018 Q2 | -7.11 Million NOK | 51.1% |
| 2018 Q1 | -14.54 Million NOK | 8.57% |
| 2017 Q4 | -15.9 Million NOK | -54.68% |
| 2017 FY | -42.84 Million NOK | -33.11% |
| 2017 Q1 | -9.63 Million NOK | -45.9% |
| 2017 Q2 | -7.02 Million NOK | 27.08% |
| 2017 Q3 | -10.28 Million NOK | -46.37% |
| 2016 Q1 | -7.13 Million NOK | 14.82% |
| 2016 FY | -32.18 Million NOK | -0.82% |
| 2016 Q4 | -6.6 Million NOK | 28.83% |
| 2016 Q3 | -9.27 Million NOK | -1.16% |
| 2016 Q2 | -9.17 Million NOK | -28.5% |
| 2015 Q3 | -9.29 Million NOK | -41.02% |
| 2015 FY | -31.92 Million NOK | 10.93% |
| 2015 Q1 | -7.65 Million NOK | 25.0% |
| 2015 Q2 | -6.59 Million NOK | 13.89% |
| 2015 Q4 | -8.37 Million NOK | 9.88% |
| 2014 Q1 | -9.24 Million NOK | -3.99% |
| 2014 Q2 | -8.13 Million NOK | 12.08% |
| 2014 Q3 | -8.25 Million NOK | -1.54% |
| 2014 Q4 | -10.2 Million NOK | -23.62% |
| 2014 FY | -35.84 Million NOK | -29.82% |
| 2013 Q1 | -6.82 Million NOK | 18.4% |
| 2013 Q2 | -5.41 Million NOK | 20.7% |
| 2013 Q3 | -6.56 Million NOK | -21.25% |
| 2013 Q4 | -8.89 Million NOK | -35.52% |
| 2013 FY | -27.6 Million NOK | -9.3% |
| 2012 Q1 | -5.52 Million NOK | -37.5% |
| 2012 Q4 | -8.36 Million NOK | -9.72% |
| 2012 Q3 | -7.62 Million NOK | -102.58% |
| 2012 Q2 | -3.76 Million NOK | 31.85% |
| 2012 FY | -25.25 Million NOK | -83.72% |
| 2011 Q1 | -3.19 Million NOK | 22.57% |
| 2011 FY | -13.74 Million NOK | 1.37% |
| 2011 Q2 | -4.29 Million NOK | -34.37% |
| 2011 Q3 | -2.23 Million NOK | 47.89% |
| 2011 Q4 | -4.01 Million NOK | -79.37% |
| 2010 Q3 | 1.94 Million NOK | 131.2% |
| 2010 Q1 | -5.52 Million NOK | -53.34% |
| 2010 FY | -13.94 Million NOK | 7.16% |
| 2010 Q2 | -6.22 Million NOK | -12.55% |
| 2010 Q4 | -4.13 Million NOK | -312.78% |
| 2009 Q4 | -3.6 Million NOK | -8.39% |
| 2009 Q3 | -3.32 Million NOK | 9.18% |
| 2009 Q2 | -3.66 Million NOK | 0.0% |
| 2009 FY | -15.01 Million NOK | -32.0% |
| 2008 FY | -11.37 Million NOK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Arctic Bioscience AS | -45.51 Million NOK | 55.366% |
| Aqua Bio Technology ASA | -19.11 Million NOK | -6.29% |
| ArcticZymes Technologies ASA | 19.42 Million NOK | 204.582% |
| BerGenBio ASA | -190.4 Million NOK | 89.33% |
| Hofseth BioCare ASA | -106.68 Million NOK | 80.958% |
| Thor Medical ASA | -26.56 Million NOK | 23.516% |
| Ultimovacs ASA | -189.23 Million NOK | 89.265% |